Targeted radiation zaps Hard-to-Treat cancers in first human trial

NCT ID NCT05283330

First seen Jan 25, 2026 · Last updated May 06, 2026 · Updated 13 times

Summary

This study tests a new drug that delivers radiation directly to cancer cells with a specific marker (GRPR). It is for adults with advanced cancers like prostate, breast, lung, or colon cancer that have come back or spread. The main goal is to find a safe dose and check for side effects. About 48 people will take part in this early-phase trial.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Advanced Molecular Imaging and Therapy

    RECRUITING

    Glen Burnie, Maryland, 21061, United States

    Contact Phone: •••-•••-••••

    Contact

  • Northwestern University Robert H Lurie Medical Research

    ACTIVE_NOT_RECRUITING

    Chicago, Illinois, 60611, United States

  • UK Markey Cancer Center

    RECRUITING

    Lexington, Kentucky, 40536, United States

    Contact Phone: •••-•••-••••

    Contact

  • XCancer Omaha / Urology Cancer Center

    RECRUITING

    Omaha, Nebraska, 68130, United States

    Contact Phone: •••-•••-••••

    Contact

Conditions

Explore the condition pages connected to this study.